Home > Annual Financials > JENBURKT PHARMACEUTICALS

JENBURKT PHARMACEUTICALS Financial Statement Analysis
[BOM: 524731]

The Revenues of JENBURKT PHARMACEUTICALS have increased by 6.85% YoY .
The Earnings Per Share (EPS) of JENBURKT PHARMACEUTICALS has increased by 23.43 % YoY.
REVENUES
OPERATING MARGIN
PROFIT AFTER TAX
EPS
ROCE

JENBURKT PHARMACEUTICALS Last 5 Annual Financial Results
[BOM: 524731]

StandaloneMar2025
Mar2024
Mar2023
Mar2022
Mar2021
Revenues ₹152 Cr₹142 Cr₹137 Cr₹124 Cr₹109 Cr
Expenses ₹111 Cr₹109 Cr₹106 Cr₹97 Cr₹89 Cr
Operating Profit (Excl OI) ₹40 Cr₹33 Cr₹30 Cr₹27 Cr₹20 Cr
Other Income ₹6.72 Cr₹4.67 Cr₹5.12 Cr₹4.95 Cr₹4.31 Cr
Interest ₹0.45 Cr₹0.27 Cr₹0.37 Cr₹0.43 Cr₹0.47 Cr
Depreciation ₹2.73 Cr₹2.34 Cr₹2.26 Cr₹1.90 Cr₹2.04 Cr
Profit Before Tax ₹44 Cr₹35 Cr₹33 Cr₹30 Cr₹22 Cr
Profit After Tax ₹32 Cr₹26 Cr₹25 Cr₹22 Cr₹17 Cr
Earnings Per Share (Rs)₹72.65₹58.86₹55.76₹48.58₹35.96
PAT Margin (%)21.1418.3017.9917.9815.10
ROE(%)20.2519.4320.5320.6618.49
ROCE(%)27.8526.2826.8026.8923.83
Total Debt/Equity(x)0.010.000.020.050.04

Key Financials

Market Cap : ₹ 603.7 Cr
Revenue (TTM) : ₹ 151.7 Cr
Net Profit(TTM) : ₹ 32.1 Cr
EPS (TTM) : ₹ 72.9
P/E (TTM) : 18.8

Industry Peers & Returns1W1M1Y
JENBURKT PHARMACEUTICALS 5.6% 21% 46.6%
SUN PHARMACEUTICAL INDUSTRIES 0.9% -0.1% 10.9%
DIVIS LABORATORIES 3.7% 3% 46.5%
CIPLA 0.2% 2.8% 1.6%
TORRENT PHARMACEUTICALS 7.3% 7.4% 19.8%
DR REDDYS LABORATORIES -4% 2.6% 7.2%
MANKIND PHARMA 0.6% -6.1% 9.3%
ZYDUS LIFESCIENCES 2.6% 6.4% -8%
LUPIN 0.4% -1.1% 22.2%


JENBURKT PHARMACEUTICALS Revenues
[BOM: 524731]

Y-o-Y

6.85 %

5 Yr CAGR

8.54 %

Years Revenues % Change
Mar2025 ₹152 Cr
6.85
Mar2024 ₹142 Cr
3.82
Mar2023 ₹137 Cr
10.30
Mar2022 ₹124 Cr
13.44
Mar2021 ₹109 Cr -


JENBURKT PHARMACEUTICALS Operating Profit
[BOM: 524731]

Y-o-Y

21.96 %

5 Yr CAGR

19.45 %

Years Operating Profit % Change
Mar2025 ₹40 Cr
21.96
Mar2024 ₹33 Cr
9.06
Mar2023 ₹30 Cr
11.42
Mar2022 ₹27 Cr
37.36
Mar2021 ₹20 Cr -

Operating Margins
Y-o-Y

14.14 %

5 Yr CAGR

10.06 %

Years Operating Margin% % Change
Mar2025 26.63%
14.14
Mar2024 23.33%
5.04
Mar2023 22.21%
1.05
Mar2022 21.98%
21.10
Mar2021 18.15% -

JENBURKT PHARMACEUTICALS Profit After Tax
[BOM: 524731]

Y-o-Y

23.42 %

5 Yr CAGR

18.06 %

Years Profit After Tax % Change
Mar2025 ₹32 Cr
23.42
Mar2024 ₹26 Cr
5.57
Mar2023 ₹25 Cr
10.36
Mar2022 ₹22 Cr
35.12
Mar2021 ₹17 Cr -

PAT Margins
Y-o-Y

15.52 %

5 Yr CAGR

8.78 %

Years PAT Margin(%) % Change
Mar2025 21.14 %
15.52
Mar2024 18.3 %
1.72
Mar2023 17.99 %
0.06
Mar2022 17.98 %
19.07
Mar2021 15.1 % -

JENBURKT PHARMACEUTICALS Earnings Per Share (EPS)
[BOM: 524731]

Y-o-Y

23.43 %

5 Yr CAGR

19.22 %

Years EPS % Change
Mar2025 ₹73
23.43
Mar2024 ₹59
5.56
Mar2023 ₹56
14.78
Mar2022 ₹49
35.09
Mar2021 ₹36 -

JENBURKT PHARMACEUTICALS Return on Capital Employed (ROCE)
[BOM: 524731]

Y-o-Y

5.97 %

5 Yr CAGR

3.97 %

Years ROCE % Change
Mar2025 27.85%
5.97
Mar2024 26.28%
-1.94
Mar2023 26.8%
-0.33
Mar2022 26.89%
12.84
Mar2021 23.83% -

JENBURKT PHARMACEUTICALS Share Price vs Sensex

Current Share Price : ₹1,372.1
Current MarketCap: ₹ 603.7 Cr
Updated EOD on :Jun 30,2025

Share Price Returns(%) 1 Week 1 Month 1 Year
JENBURKT PHARMACEUTICALS

5.6%

21%

46.6%

SENSEX

2.1%

2.4%

7.1%

JENBURKT PHARMACEUTICALS related INDICES

No BSE index found!
No NSE index found

You may also like the below Video Courses


FAQ about JENBURKT PHARMACEUTICALS Financials


How the annual revenues of JENBURKT PHARMACEUTICALS have changed ?

The Revenues of JENBURKT PHARMACEUTICALS have increased by 6.85% YoY .

How the Earnings per Share (EPS) of JENBURKT PHARMACEUTICALS have changed?

The Earnings Per Share (EPS) of JENBURKT PHARMACEUTICALS has increased by 23.43 % YoY .